Marvell Rebounds as UBS Reframes Its Bull Case Around CXL and Lifts Target to $340

The Catalyst: UBS Pivots the Thesis to CXL

The 9.80% move is an analyst-driven rebound, not a reaction to anything Marvell itself announced. On June 29, UBS lifted its Marvell target to $340 from $230 while keeping a Buy rating, and the framing matters as much as the number. Analyst Timothy Arcuri reset the story around Compute Express Link (CXL), the memory-pooling interconnect for AI servers, rather than the headline custom-silicon narrative everyone already owns.

The math behind the call is aggressive. UBS now models the CXL market reaching roughly $4.5 billion by 2027 and $7–10 billion by 2030, with Marvell, which holds leading share in CXL products today, capturing about $1 billion of CXL revenue in 2027 and scaling toward $2 billion by 2028. Yet the firm only nudged FY2027 and FY2028 revenue estimates to $16.8 billion and $23.9 billion, from $16.5 billion and $21.9 billion. Modest top-line revisions against a near-50% target bump tell you the re-rate is about multiple, not numbers.

Why This Is a Theme Trade, Not Company News

The tell that this is a sector bid: Arcuri raised the call on two names at once. UBS also took Astera Labs to $400 from $205 (kept Neutral), and ALAB closed up roughly 16% on the same note, outrunning Marvell's move. When two stocks rip on one analyst's CXL thesis, you're trading the theme, not the company.

There is a real fundamental hook underneath, though. Marvell recently closed its acquisition of CXL switch maker XConn Technologies alongside optical-compute startup Celestial AI, with Nvidia layering in a roughly $2 billion equity stake. The XConn deal slots directly into the CXL narrative UBS is now underwriting, so the timing of the upgrade isn't an accident, it's the sell-side catching up to a portfolio Marvell already assembled.

The Setup: Buying Back a CFO-Sale Dip

Context for the size of the bounce: this reverses most of a brutal week. On June 26, Marvell was the worst performer in the S&P 500, dropping nearly 10% after outgoing CFO Willem Meintjes filed a Form 144 to sell 211,329 shares, a disclosure that landed on top of quarter-end rebalancing and broad high-beta semiconductor selling. The UBS note gave dip-buyers the cover to step back in.

Zoom out and the tape is whippy for a reason. Marvell is up roughly 265% in 2026, joined the S&P 500 on June 22, and now trades on analyst targets that keep leapfrogging the price, with Bank of America resetting higher and KeyBanc at a Street-high $385. With index-inclusion demand drained and the float changing hands on sell-side enthusiasm rather than guidance, expect the low-to-mid $280s to stay a battleground until there's actual company news to anchor to.